Actively Recruiting
68Ga-MY6349 PET/CT in Solid Tumors and Compared With 18F-FDG PET/CT
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-07-15
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new imaging method using 68Ga-MY6349 PET/CT to detect Trop-2 expression in tumor lesions of patients with solid tumors. This study aims to compare the effectiveness of this new PET radiotracer with the standard 18F-FDG PET/CT imaging to identify patients who may benefit from Trop-2 targeted imaging. The study is observational and involves patients with various types of malignant tumors, either newly diagnosed or previously treated. Participants receive a single intravenous injection of the 68Ga-MY6349 tracer and then undergo PET/CT imaging within a set timeframe. They also undergo standard-of-care imaging with 18F-FDG PET/CT either for initial assessment or to detect tumor recurrence. The uptake of the tracer in tumors is measured by the maximum standard uptake value (SUVmax) and compared visually to the standard imaging results. During the study, researchers will assess the feasibility of using 68Ga-MY6349 PET/CT for non-invasive evaluation of Trop-2 expression in tumors. Participants will have both imaging tests and their tumor lesions will be documented and analyzed. The primary focus is on imaging accuracy and tracer uptake within one week. This study is sponsored by The First Affiliated Hospital of Xiamen University and involves adults aged 18 years or older with solid tumors.
CONDITIONS
Brief Title
68Ga-MY6349 PET/CT in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors confirmed by MRI, CT, tumor markers, or pathology report
- Patients scheduled for both standard-of-care imaging and 68Ga-MY6349 PET/CT scans
- Patients able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients who are pregnant
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 week
Participants receive a single intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging along with standard-of-care imaging for assessment of tumor activity.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here